Socialiya - Entertainment. Knowledge. Community.
Revolution Medicines shares promising data around KRAS drug combination

Revolution Medicines' Phase 1 data on combining zoldonrasib with daraxonrasib in pancreatic cancer s...

BUSINESS NEWS July 02, 2026

Revolution Medicines shares promising data around KRAS drug combination

Revolution Medicines' Phase 1 data on combining zoldonrasib with daraxonrasib in pancreatic cancer support a planned Phase 3 trial, as the KRAS field grows...

1 views 0 likes 0 comments
Share:
Revolution Medicines' Phase 1 data on combining zoldonrasib with daraxonrasib in pancreatic cancer support a planned Phase 3 trial, as the KRAS field grows...

Author: Endpoints News

Read Original Article

Related News

Advertisement
APNA POS
Advertisement
socialiya
Advertisement

Top Categories

Advertisement
socialiya
Advertisement
socialiya
Advertisement
APNA POS
Advertisement
APNA POS